Last Updated: 02/12/2024
Controlled Human Malaria Infection Model for Evaluation of Transmission‐Blocking Interventions – Study 1 (CHMI-trans1)
Objectives
The primary aim of this project is to develop a controlled human malaria infection transmission model (“CHMI-trans”) or “challenge model” to evaluate the capacity of vaccines, biologics (monoclonal antibodies, or mAbs), and drugs to block malaria parasite transmission by assessing infectiousness of Plasmodium falciparum (Pf) gametocyte carriers for Anopheles mosquitoes.
Principal Institution
Partner Institutions
PATH, United States
QIMR Berghofer Medical Research, Australia
Study Design
ClinicalTrials.gov Identifier: NCT02836002
Study Type: Interventional
Study Phase: Phase 1, Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Project Outputs
External reference
Date
Jun 2016 — Jun 2017
Country / Project Site(s)
Deep Dives
Related Resources
